DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Cabozantinib
Cabozantinib
PD-L1 Expression and Clinical Outcomes to Cabozantinib
Management of Brain and Leptomeningeal Metastases from Breast Cancer
BC Cancer Benefit Drug List September 2021
Dual Inhibition Using Cabozantinib Overcomes HGF/MET Signaling Mediated Resistance to Pan-VEGFR Inhibition in Orthotopic and Metastatic Neuroblastoma Tumors
CELEBRATING 25 YEARS of PROGRESS for PATIENTS for PROGRESS of YEARS 25 CELEBRATING Annual Report 2019 Report Annual
(FDA) Approved Bristol Myers Squibb's (Bms.Com) Br
KCI Protocol # 2011-185 Pilot Trial of Oral Cabozantinib/ XL184 In
ESMO E-Learning Next Generation Drugs in Kidney Cancer
5.01.534 Multiple Receptor Tyrosine Kinase Inhibitors
Cancer Drug Costs for a Month of Treatment at Initial Food
Summary of Risk Management Plan for Cometriq (Cabozantinib)
Medullary Thyroid Cancer Agents – Unified Formulary
Vandetanib for the Treatment of Medullary Thyroid Cancer
Thyroid Cabozantinib
Augmentation of Nab-Paclitaxel Chemotherapy Response By
Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
Drug-Drug Interactions of Common Chemotherapeutic Agents And
Cabozantinib for Untreated Metastatic Renal Cell Carcinoma
Top View
Drug Policy: Cometriq/Cabometyx ™ (Cabozantinib)
Cabozantinib) Tablets, for Oral Use And/Or Permanently Discontinuing the Combination for Severe Or Life- Initial U.S
Anticancer Drug-Induced Thyroid Dysfunction
Targeted Therapy in Metastatic Bladder Cancer: Present Status and Future Directions
The Anti-Tumor Effect of Cabozantinib on Ovarian Clear Cell Carcinoma In
Cabometyx (Cabozantinib)
Australian Public Assessment Report for Cabozantinib
Anlotinib: a Novel Multi-Targeting Tyrosine Kinase Inhibitor in Clinical Development
The Proto-Oncogene C-Kit Inhibits Tumor Growth by Behaving As a Dependence Receptor Hong Wang
Cabozantinib Is Predominantly Oxidized by CYP3A4 and Its Oxidation Is Stimulated by Cyt B5 Activity
Renal Cell Carcinoma Treatment Regimens
Cabozantinib
Cabozantinib Suppresses Tumor Growth and Metastasis in Hepatocellular Carcinoma by a Dual Blockade of VEGFR2 and MET
208692Orig1s000
Adult Antiemetic Management of Chemotherapy-Induced Nausea
Individualization of Dose and Schedule Based on Toxicity for Oral VEGF Drugs in Kidney Cancer
Financial Results Presentation
Press Release
Cabozantinib: a Novel Tyrosine Kinase Receptor Inhibitor for the Treatment for Advanced Renal Cell Carcinoma
PRESCRIBING INFORMATION • QT Interval Prolongation: Monitor Patients Who Are at Significant Risk of Developing Qtc Prolongation
Targeting Tyrosine Kinases in Acute Myeloid Leukemia: Why, Who and How?
Beyond First-Line Immunotherapy: Potential Therapeutic Strategies Based on Different Pattern Progressions: Oligo and Systemic Progression
Precision Targeted Therapy with BLU-667 for RET-Driven Cancers
Cabozantinib (Cometriq™)
Targeted Therapies for Previously Treated Advanced Or Metastatic Renal Cell Carcinoma: Systematic Review and Network Meta-Analysis
Repurposing Cabozantinib to Gists Overcoming Multiple Imatinib
CABOMETYX, INN-Cabozantinib
Axitinib, Cabozantinib, Or Everolimus in the Treatment Of
Activity of Cabozantinib in Radioresistant Brain Metastases
Cabozantinib and Vandetanib for Unresectable Locally Advanced Or Metastatic Medullary Thyroid Cancer: a Systematic Review and Economic Model
About Rearranged During Transfection in Non-Small Cell Lung Cancer
Cabozantinib and Vandetanib for Treating Medullary Thyroid Cancer
Cabozantinib
[2016]. NIOSH List of Antineoplastic and Other Hazardous Drugs in Healthcare Settings, 2016
The Use of Cabozantinib in Advanced Hepatocellular Carcinoma in Hong Kong—A Territory-Wide Cohort Study
Study Protocol, As Applicable
Cabozantinib for Untreated Advanced Renal Cell Carcinoma
Cometriq Full Prescribing Information
Investigational Chemotherapy and Novel Pharmacokinetic Mechanisms for the Treatment of Breast Cancer Brain Metastases
Latest PDF of Open Trials
Recognizing and Managing the Toxicities of Treatment for Renal Cell Carcinoma
Cabozantinib Is Active Against Human Gastrointestinal Stromal Tumor Xenografts Carrying Different KIT Mutations Yemarshet K
Repurposing Cabozantinib with Therapeutic Potential in KIT-Driven T(8;21) Acute Myeloid Leukaemias
Drug-Related Pneumonitis in Cancer Treatment During the COVID-19 Era
Health Canada Approves Ipsen's CABOMETYXTM (Cabozantinib) For
All ETCTN Trials
Cost-Effectiveness of Cabozantinib Versus Sunitinib Or Pazopanib As
Axitinib, Cabozantinib, Everolimus
Publication Agenda CHMP 07-10 December 2020
Pharmacological Research the Role of Small Molecule Kit Protein-Tyrosine
Update on Molecular Genetics of Gastrointestinal Stromal Tumors
Thyroid Effects of Tyrosine Kinase Inhibitors
A Novel Kindred with Familial Gastrointestinal Stromal Tumors Caused by a Rare KIT Germline Mutation (N655K): Clinico-Pathological Presentation and TKI Sensitivity
FDA Updates Highlighting the Latest Cancer Treatments